Posted by Michael Wonder on 31 Jan 2023
Ionis receives FDA fast track designation for olezarsen in patients with familial chylomicronaemia syndrome
31 January 2023 - If approved, olezarsen would be the first approved treatment for familial chylomicronaemia syndrome in the US.
Ionis Pharmaceuticals today announced that the US FDA has granted olezarsen fast track designation for the treatment of familial chylomicronaemia syndrome.
